This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should Value Investors Buy Owens & Minor (OMI) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Medtronic Launches Kyphon Cannula for Balloon Kyphoplasty
by Zacks Equity Research
Medtronic's (MDT) new cannula will complement its entire portfolio of balloon kyphoplasty products, including Kyphon Xpander II Inflatable Bone Tamps.
Here's Why You Should Hold on to Illumina (ILMN) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Illumina (ILMN) on its focus on partnerships and robust demand for its products.
ResMed (RMD) Launches Digital Tool for Remote Mask Selection
by Zacks Equity Research
Based on a brief questionnaire remotely filled by the patient, the MaskSelector tool recommends the best suitable ResMed (RMD) mask for patients.
Neogen (NEOG) Introduces Upgraded Igenity Beef Genomic Profile
by Zacks Equity Research
Neogen (NEOG) looks to provide better technology and information to commercial beef producers to take better decisions for their profitability.
Here's Why You Should Hold on to ResMed (RMD) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about ResMed (RMD) on its focus on digital health technology and robust demand for its critical care products.
Myriad's (MYGN) EndoPredict Grows Amid Coronavirus Mayhem
by Zacks Equity Research
Within Molecular Diagnostics, Myriad Genetics (MYGN) registers strong sales for EndoPredict, myChoice CDx and BRACAnalysis CDx.
Hologic's Second Molecular Test Gets EUA to Detect Coronavirus
by Zacks Equity Research
Hologic (HOLX) expects to boost testing capacity by combining its manufacturing ability for the latest EUA of test with its largest installed base of high-throughput molecular instruments.
Should Value Investors Buy Owens & Minor (OMI) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Owens & Minor (OMI) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Owens & Minor (OMI) delivered earnings and revenue surprises of 300.00% and 0.40%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Why Owens & Minor (OMI) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Owens & Minor (OMI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Analysts Estimate Owens & Minor (OMI) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Owens & Minor (OMI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Owens & Minor (OMI) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Owens & Minor (OMI) closed at $6.76 in the latest trading session, marking a -0.29% move from the prior day.
Company News for Mar 31, 2020
by Zacks Equity Research
Companies In The News Are: SPCB, OMI, CVU, REGN
Implied Volatility Surging for Owens & Minor (OMI) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Owens & Minor (OMI) stock based on the movements in the options market lately.
Owens & Minor (OMI) Stock Moves -1.35%: What You Should Know
by Zacks Equity Research
Owens & Minor (OMI) closed the most recent trading day at $5.83, moving -1.35% from the previous trading session.
Owens & Minor (OMI) Surpasses Q4 Earnings Estimates
by Zacks Equity Research
Owens & Minor (OMI) delivered earnings and revenue surprises of 9.09% and -12.14%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Owens & Minor (OMI) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Owens & Minor (OMI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Owens & Minor (OMI) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Owens & Minor (OMI) closed the most recent trading day at $6.96, moving +0.14% from the previous trading session.
Are Investors Undervaluing Owens & Minor (OMI) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Trump Mulling Tax Cuts to Incentivize Stock Buying? 6 Picks
by Nalak Das
President Trump's tenure has seen Wall Street perform exceptionally well so far. In fact, Trump often cites Wall Street's bull run as a reflection of his good governance.
Small-Cap Healthcare ETF Outperforming in 2020: 5 Top Stocks
by Sweta Killa
The small-cap healthcare companies are benefiting from the 2020 presidential election campaign, which has put pressure on the large cap cousins on how to overhaul the industry.
Top Ranked Value Stocks to Buy for February 12th
by Zacks Equity Research
Here are four stocks with buy rank and strong value characteristics for investors to consider today, February 12th
Wix, Wynn Resorts, Beyond Meat, Owens & Minor and Advantest highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Wix, Wynn Resorts, Beyond Meat, Owens & Minor and Advantest highlighted as Zacks Bull and Bear of the Day
Beyond Meat Shooting Beyond Expectations
by Sejuti Banerjea
Beyond Meat is an exciting company with huge growth prospects, but it's a risky investment.